Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39050
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBenedict, R. H.-
dc.contributor.authorComi, G.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorSiva, A.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWiendl, H.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorKuenzel, T.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2022-12-15T11:02:37Z-
dc.date.available2022-12-15T11:02:37Z-
dc.date.issued2022-
dc.date.submitted2022-12-09T12:47:15Z-
dc.identifier.citationMultiple Sclerosis Journal, 28 (S3) , p. 392 -393-
dc.identifier.urihttp://hdl.handle.net/1942/39050-
dc.description.sponsorshipSponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK. RHB Benedict has received research support from Biogen, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Genzyme, Genentech, Novartis, National Institutes of Health, National Multiple Sclerosis Society and VeraSci; consultancy fees from Immunic Therapeutics, Latin American Committee for Treatment and Research in Multiple Sclerosis, Merck, Novartis, and Sanofi; speaking support from Biogen, Bristol Myers Squibb and EMD Serono; and royalties from Psychological Assessment Resources, Inc.-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleCognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateOCT 26-28, 2022-
local.bibliographicCitation.conferencename38th Congress of the-
local.bibliographicCitation.conferencenameEuropean-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis-
local.bibliographicCitation.conferenceplaceAmsterdam, NETHERLANDS-
dc.identifier.epage393-
dc.identifier.issueS3-
dc.identifier.spage392-
dc.identifier.volume28-
local.format.pages2-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000866540801374-
local.provider.typewosris-
local.description.affiliation[Benedict, R. H.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, Buffalo, NY USA.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.description.affiliation[Comi, G.] Casa Cura Policlin, Milan, Italy.-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Siva, A.] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey.-
local.description.affiliation[Van Wijmeersch, B.] Hasselt Univ, Univ MS Ctr, Pelt, Hasselt, Belgium.-
local.description.affiliation[Wiendl, H.] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany.-
local.description.affiliation[Buffels, R.; Kuenzel, T.] F Hoffmann La Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Vermersch, P.] Univ Lille, CHU Lille, INSERM, U1172,LilNCog,FHU Precise, Lille, France.-
local.uhasselt.internationalyes-
item.fullcitationBenedict, R. H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuenzel, T. & Vermersch, P. (2022) Cognitive improvements in ocrelizumab-treated patients with relapsing-remitting multiple sclerosis: 96-week CASTING study data. In: Multiple Sclerosis Journal, 28 (S3) , p. 392 -393.-
item.contributorBenedict, R. H.-
item.contributorComi, G.-
item.contributorOreja-Guevara, C.-
item.contributorSiva, A.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWiendl, H.-
item.contributorBuffels, R.-
item.contributorKuenzel, T.-
item.contributorVermersch, P.-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Cognitive improvements in ocrelizumab-treated.pdfPublished version4.46 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.